Aziyo Biologics, Inc. provided sales guidance for the year 2022. For the year, the company expects total net sales for the full year 2022 will be in the range of $47 million to $50 million. Excluding approximately $4.9 million of FiberCel sales in 2021, this range represents expected growth of 11% to 18%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.975 USD | +0.25% | +20.55% | +86.57% |
05-09 | Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.57% | 96.55M | |
-1.54% | 91.26B | |
-2.63% | 38.17B | |
+69.33% | 26.74B | |
-11.89% | 15.93B | |
-4.67% | 13.37B | |
-10.50% | 11.77B | |
+187.82% | 10.92B | |
-49.11% | 10.27B | |
+0.82% | 8.69B |
- Stock Market
- Equities
- ELUT Stock
- News Elutia Inc.
- Aziyo Biologics, Inc. Provides Sales Guidance for the Year 2022